ArticleACS omega2026
The Impact of Surfactants in Tailoring Nanostructured Lipid Carriers for Inhaled Levofloxacin.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanoparticles can enhance pulmonary delivery of antibiotics by modifying or targeting drug release, increasing drug stability, decreasing mucus entrapment, disrupting biofilms, and reaching the deep lung. Surfactants play a key role as coating agents for several nanoparticle types, modulating interfacial interactions with drugs and the environment. Specifically, levofloxacin (LV) inhalation can benefit from its loading into nanostructured lipid carriers (NLCs) for high drug entrapment, sustained release, and antimicrobial efficacy, but no studies have focused on the relevance of the surfactant type on its biological and physicochemical performance. Therefore, this study aimed to evaluate the impact of three nonionic surfactantspolysorbate 80 (P80), poloxamer 407 (P407), and poloxamer 188 (P188)on the physicochemical and biological
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.